Avicanna Inc
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Avicanna Inc. operates as a commercial-stage biopharmaceutical enterprise, dedicated to the global research, development, and commercialization of advanced cannabinoid-based offerings for medical and pharmaceutical segments. The company cultivates a robust scientific foundation, collaborating with prominent Canadian academic and clinical institutions, driving a pipeline that has yielded over thirty proprietary, evidence-based finished products across four key commercial pillars. Its diverse product portfolio encompasses the RHO Phyto™ medical cannabis formulary, providing a spectrum of oral, sublingual, topical, and transdermal delivery systems featuring various ratios of CBD, CBG, and THC. Avicanna also manages MyMedi.ca, a dedicated medical cannabis care platform offering extensive product selections and pharmacist-led patient support. Furthermore, the company supplies active pharmaceutical ingredients (APIs), including CBD, THC, and CBG, sourced sustainably from its Colombian cultivation operations under the Aureus Santa Marta™ brand, serving international partners. Avicanna maintains an active pharmaceutical pipeline, advancing proprietary cannabinoid-based drug candidates through various clinical stages to address unmet medical needs in areas such as dermatology, chronic pain, and diverse neurological conditions. Recent advancements include preclinical data and patent filings for a novel oral drug delivery platform designed to enhance cannabinoid absorption, alongside issued U.S. patents for topical pain relief compositions and self-emulsifying drug delivery systems. The company has also sponsored a pilot Phase II clinical study investigating oral cannabis extracts for osteoarthritis pain. With a focus on expanding its global footprint, Avicanna has successfully commercialized its products into twenty-three international markets. Recent corporate milestones include achieving its first profitable quarter in Q1 2025 and reporting record revenue of $25.5 million for the full year 2024, reflecting growth in both Canadian and international operations. Strategic collaborations, such as a scientific and medical affairs agreement with Vectura Fertin Pharma, a subsidiary of Philip Morris International, and a partnership with the Nurse Practitioners' Association of Ontario for medical cannabis education, underscore its commitment to scientific validation and market penetration. Established in Toronto, Canada, in 2016, Avicanna continues to emphasize an evidence-based approach in the evolving cannabinoid biopharmaceutical landscape.
Company News
Avicanna Transitions US Listing to OTCQB
Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026
Short Interest in Avicanna Inc. (OTCMKTS:AVCNF) Rises By ∞
Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada
Avicanna Announces Closing of Strategic Non-Brokered Private Placement
Avicanna Reports Q2 2026 Financial Results
Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio
Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer
Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare
Avicanna Announces Closing of Non-Brokered Private Placement
Avicanna Reports Q1 2026 Financial Statements
Avicanna Inc. (AVCN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Avicanna Announces Results of Annual General and Special Meeting
Avicanna Announces Change in Board of Directors
Avicanna Announces Change in Board of Directors
Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update
Annual General and Special Meeting of Shareholders to be held May 7, 2026
ThreeD Capital Inc. Issues Early Warning Report in Connection with Disposition of Securities of Avicanna Inc.
Avicanna Inc. (AVCN:CA) Q4 2025 Earnings Call Transcript
Avicanna Announces Changes to its Board of Directors